Compare Ticagrelor vs Clopidogrel on the Reduction of Arterial Stiffness and Wave Reflectionsin Patients With Coronary Artery Disease . The NOVELTY Study (NOVELTY)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02071212
Recruitment Status : Recruiting
First Posted : February 25, 2014
Last Update Posted : March 3, 2017
Information provided by (Responsible Party):
Hellenic Cardiovascular Research Society

Brief Summary:
The purpose of this study is to investigate the potential acute and chronic effect of ticagrelor versus clopidogrel on arterial stiffness and other vascular risk markers of interest, the study will consist of two periods: a 24-hour ACUTE period where 60 subjects with an indication for coronary angiography (CA) with or without percutaneous coronary intervention (PCI) will be included, and a 30-day CHRONIC period where approximately 60 subjects that will undergo PCI will be included and studied (refer to Section 3 'Study Plan and Procedures'). The primary objective of this study is to compare ticagrelor versus clopidogrel regarding their effect on arterial stiffness as assessed by PWV, at 3 hours after the loading dose of each regimen, in eligible subjects with CAD.

Condition or disease Intervention/treatment Phase
Coronary Artery Disease Drug: Ticagrelor Phase 2

  Show Detailed Description

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 120 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Single Center Phase II Assessor -Blinded RaNdomised Active Controlled Parallel-Group Trial to COmpare Ticagrelor Versus Clopidogrel on the REduction of ArteriaL STiffness and Wave Reflections in Patients With CoronarY Artery Disease. The NOVELTY Study
Study Start Date : February 2014
Estimated Primary Completion Date : June 2017
Estimated Study Completion Date : June 2017

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Active Comparator: Clopidogrel
Loading dose 600 mg .Mainatinance dose 75 mg QD
Drug: Ticagrelor
Loading dose 180 mg . Maintainance dose 90 mg BID
Other Name: BRILIQUE
Experimental: Ticagrelor
Loading dose 180 mg . Maintenance 90 mg BID
Drug: Ticagrelor
Loading dose 180 mg . Maintainance dose 90 mg BID
Other Name: BRILIQUE

Primary Outcome Measures :
  1. Mean Change in the cfPWV [ Time Frame: at 3 hours after the loading dose ]
    The primary outcome is the treatment difference in the mean change in cfPWV from baseline (0 hours) at 3 hours after the loading dose of each regimen, in ticagrelor and clopidogrel acute period populations.

Secondary Outcome Measures :
  1. mean change in the cfPWV [ Time Frame: from baseline at 24 hours after the loading dose ]
    The treatment difference in the mean change in the cfPWV from baseline (0 hours) at 24 hours after the loading dose of each regimen, in the acute period populations;

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 79 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Provision of informed consent prior to any study specific procedures.
  2. Male and female subjects > 18 and < 79 years of age.
  3. Indication for elective coronary angiography (angina, positive stress test/SPECT/stress echo) with or without PCI for inclusion in the 'acute' study period, and indication for either ad hoc or elective PCI for inclusion in the 'chronic' study period.

Exclusion Criteria:

  1. Who had ACS within 12 months of screening.
  2. Previous stent implantation with dual antiplatelet therapy within 12 months of screening.
  3. Subjects being treated with anti-platelet medications other than aspirin prior to diagnostic catheterization including glycoprotein IIb/IIIa inhibitors.
  4. Subjects with NYHA class III or IV heart failure or known left ventricular ejection fraction < 30%.
  5. Subjects with hemodynamic or electrical instability (including shock).
  6. History of gastrointestinal bleeding, genitourinary bleeding or other site abnormal bleeding within the previous 6 months.
  7. Other bleeding diathesis, or considered by Investigator to be at high risk for bleeding.
  8. Any previous history of ischemic or hemorrhagic stroke, intracranial hemorrhage or disease (neoplasm, arteriovenous malformation, aneurysm).
  9. International Normalized Ratio (INR) known to be >1.5 within 1 week of study entry.
  10. Poorly controlled blood pressure (>160/100 mmHg).
  11. Known platelet count of <100,000/mm3 within 1 week of study entry.
  12. Known anemia (hemoglobin [Hb] <10 gr/dL) within 1 week of study entry.
  13. Subjects receiving daily treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) or cyclooxygenase-2 (COX-2) inhibitors that cannot be discontinued for the duration of the study.
  14. Severe kidney disease (GFR<30 ml/min/1.73m2).
  15. Hepatic insufficiency defined as liver cirrhosis, AST/ALT/Alkaline Phosphatase greater than 3 times the upper limit of normal or hyperbilirubinemia defined as peak total serum bilirubin greater than 2 times the upper limit of normal (ULN).
  16. Any indication (atrial fibrillation, mitral stenosis or prosthetic heart valve, pulmonary embolism (PE), deep vein thrombosis (DVT)) for anticoagulation treatment during study period.
  17. Asthma or chronic obstructive pulmonary disease requiring brochodilating agents.
  18. Concomitant use of potent Cytochrome P450 3A4 (CYP3A4) inhibitors (atazanavir, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin and voriconazole) or inducers (carbamazepine, dexamethasone, phenobarbital, phenytoin, rifampin, and rifapentine).
  19. Concomitant use of drugs that are metabolized through CYP2C19 (omeprazole and esomeprazole, fluvoxamine, fluoxetine, moclobemide, voriconazole, fluconazole, ticlopidine, ciprofloxacin, cimetidine, carbamazepine, oxcarbazepine and chloramphenicol).
  20. History of uric acid nephropathy and high levels of uric acid within 1 week of study entry.
  21. Increased risk of bradycardic events (e.g. known sick sinus syndrome or third degree AV block or previous documented syncope suspected to be due to bradycardia unless treated with a pacemaker).
  22. Known neoplastic or autoimmune disease or any concomitant medical illness that in the opinion of the Investigator may interfere with or prevent completion in this study.
  23. Contraindication to clopidogrel, ASA, or ticagrelor.
  24. A history of alcohol and/or substance abuse that could interfere with conduct of the trial.
  25. Pregnancy or lactation (for premenopausal women 2 methods of reliable contraception, one of which must be barrier method, are required).
  26. Treatment with other investigational agents (including placebo) or devices within 30 days prior to randomization or planned use of investigational agents or devices prior to the Day 30 visit.
  27. Life expectancy less than 1 year.
  28. Indication for major surgery (e.g. cancer treatment, carotid surgery, cerebral surgery, major vascular surgery).
  29. High likelihood of being unavailable for the Day 30 follow up.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02071212

Contact: Charalambos Vlachopoulos, Associate Prof

Ippokratio Hospital Recruiting
Athens, Greece
Principal Investigator: Charalambos Vlachopoulos, Associate Professor         
Sponsors and Collaborators
Hellenic Cardiovascular Research Society
Principal Investigator: Charalambos Vlachopoulos Ippokratio Hospital Athens , Greece

Responsible Party: Hellenic Cardiovascular Research Society Identifier: NCT02071212     History of Changes
Other Study ID Numbers: D5130L00063
First Posted: February 25, 2014    Key Record Dates
Last Update Posted: March 3, 2017
Last Verified: March 2017

Additional relevant MeSH terms:
Coronary Artery Disease
Myocardial Ischemia
Coronary Disease
Heart Diseases
Cardiovascular Diseases
Arterial Occlusive Diseases
Vascular Diseases
Platelet Aggregation Inhibitors
Purinergic P2Y Receptor Antagonists
Purinergic P2 Receptor Antagonists
Purinergic Antagonists
Purinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs